ACC.24: Late-Breaking Science Video Collection
Published: 06 April 2024
-
Views:
4745
-
Likes:
7
-
Views:
4745
-
Likes:
7
-
Up Next -
3m 40s -
7m 18s -
6m 40sPart 3 | Session 5 Chelation Therapy in Post-MI Pts with Diabetes: TACT2 -
6m 41sPart 3 | Session 6 Semaglutide in Patients with HfpEF, Obesity and Diabetes: STEP HFpEF -
5m 41sPart 3 | Session 7 Self-Expanding vs Balloon Expandable TAVR: The SMART Trial -
3m 37s -
4m 35sPart 3 | Session 9 Technology-Assisted Nonprescription Rosuvastatin: TACTiC -
4m 45sPart 3 | Session 10 Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC -
2m 30sPart 3 | Session 11 TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6 -
4m 17s
-
6m 45sPart 4 | Session 1 Artificial Intelligence in Cardiology: What You Need to Know in 2024 -
6m 21sPart 4 | Session 2 Weight Loss Medications: What You Need to Know in 2024
-
Part 5 Coming Soon
-
43m 48sPart 1 | Session 1 ACC.24 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
28m 9sPart 1 | Session 2 What's Hot at ACC.24? Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
22m 43sPart 2 | Session 1 Late-Breaker Discussion: The EMPACT-MI Trial Harriette Van Spall, Javed Butler
-
14m 7sPart 2 | Session 2 Late-Breaker Discussion: The AEGIS-II Trial Michael C Gibson, Harriette Van Spall
-
29m 8sPart 2 | Session 3 Late-Breaker Discussion: The RELIEVE-HF Trial Gregg Stone, Harriette Van Spall
-
23m 6sPart 2 | Session 4 Late-Breaker Discussion: The ARISE-HF Trial Harriette Van Spall, James L Januzzi
-
5m 50sPart 3 | Session 1 Gamification and Financial Incentives to Increase PA Among Patients at Elevated Cardiovascular Risk Alexander Fanaroff
Overview
Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.
To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.
For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
More from this programme
Part 1
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24.
Part 2
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.
Part 3
Expert Interviews
Expert Interviews conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Part 4
Highlights
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
| 1 session | |
| Coming Soon | Watch now |
About the episode
ACC.24 — We are joined onsite by investigator, Dr Akshay Desai (Brigham and Women's Hospital, US) to discuss the findings from the KARDIA-2 randomized clinical trial (NCT05103332).
KARDIA-2 is a double-blind, placebo-controlled multicenter study aiming to evaluate the effects of zilbesiran, an RNA interference agent, on the systolic and diastolic blood pressure of hypertensive patients not adequately controlled by a standard-of-care antihypertensive medication.
672 patients were enrolled in the study, who were randomized to recieve treatment with either indapamide 2.5mg daily, amlodopine 5mg daily or olmesartan 40mga daily. After a run-in period, these arms were then again randomized to recieve either zilbesiran 60mg SC or placebo, in addition to indapamide, amlodopine or olmesartan.
Findings showed that treatment with a single subcutaneous dose of zilbesiran 600mg was associated with clinically significant reductions in 24 hour mean ambulatory and office systolic blood pressure compared with placebo at 3 months, when added to a diuretic, calcium channel blocker or maximum-dose angiotensin receptor blocker. This difference was sustained to 6 months in the indapamide and amlodipine cohorts despite add-on hypertensive therapy.
Interview questions:
1. What is the importance of this study?
2. Why is this drug needed?
3. What is the patient population and study design?
4. What are your key findings?
5. What are the clinical implications of these findings?
6. What remaining questions will KARDIA-3 answer?
Recorded onsite at the ACC Conference in Atlanta, 2024.
Faculty Biographies
Akshay S Desai
Prof Akshay Desai is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions.
Prof Desai received his medical degree from HMS. He completed an internal medicine residency as well as fellowships in cardiovascular medicine, vascular medicine and advanced heart disease at BWH. He is board certified in and cardiovascular disease, as well as advanced heart failure and transplant cardiology.
His clinical interests include advanced heart failure, cardiomyopathies (myocarditis, amyloidosis, sarcoidosis), congenital heart disease and cardiac transplantation. His research has received support from the American College of Cardiology and the National Heart, Lung and Blood Institute.
Comments